{
    "symbol": "IMGN",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-06 13:12:11",
    "content": " As we progress towards our goal of becoming a global fully integrated oncology company, since the start of the year, we've also continued enrollment in the confirmatory Phase III MIRASOL and Phase II PICCOLO studies with mirv monotherapy, expanded our commercial team and accelerated launch preparations in anticipation of a mirv approval, further accrued patients in our pivotal CADENZA study of pivek and BPDCN, initiated expansion cohorts in both relapsed and frontline AML patients combining pivek with azacitidine and venetoclax and progressed our earlier-stage programs, IMGC936 and IMGN151."
}